Madrigal Pharmaceuticals, Inc. MDGL Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s other income (expense)?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported other income (expense) of -$2.09M in Q1 2026.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s other income (expense)?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s other income (expense) has grown at a 14.1% compound annual growth rate (CAGR), from $273K to -$463K.
- What does other income (expense) mean?
- The net total of all miscellaneous income and expenses not related to core operations.
- How do you interpret other income (expense)?
- Fluctuations here are usually non-recurring; large values warrant investigation to determine if they represent one-time events or recurring non-operating trends.
- How does other income (expense) compare across companies?
- This metric is highly company-specific and varies significantly based on unique non-operating events.